Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 4c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.75), $0.04 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $10.28 million versus the consensus estimate of $13.12 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Robinhood plans $2B convertible notes offering due 2029
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight